Form D — Cadrenal Therapeutics, Inc.
0001213900-26-040457 · filed Apr 6, 2026
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- Rule 506(b)
- Reported offering amount
- $7,923,235
- Reported amount sold
- $7,923,235
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Cadrenal Therapeutics, Inc.
- CIK
- 1937993
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- 2022
- Address
- 822 A1A NORTH, SUITE 306
PONTE VEDRA, Florida 32082 - Phone
- (904) 300-0701
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Quang X. Pham · Executive OfficerPonte Vedra, Florida Find on LinkedIn ↗
-
Matthew Szot · Executive OfficerPonte Vedra, Florida Find on LinkedIn ↗
-
James Ferguson · Executive OfficerPonte Vedra, Florida Find on LinkedIn ↗
-
Jeffrey Cole · Executive OfficerPonte Vedra, Florida Find on LinkedIn ↗
-
John R. Murphy · DirectorPonte Vedra, Florida Find on LinkedIn ↗
-
Steven Zelenkofske · DirectorPonte Vedra, Florida Find on LinkedIn ↗
-
Glynn Wilson · DirectorPonte Vedra, Florida Find on LinkedIn ↗
-
Lee Golden · DirectorPonte Vedra, Florida Find on LinkedIn ↗
Other filings from this issuer
View the original filing on SEC EDGAR ↗